Basilea reports strong financial results 2022 based on
22% year-on-year increase of royalty income from antifungal Cresemba®Operating profit of CHF 18.5 million and net profit of CHF 12.1 millionStrengthened......
Continued strong Cresemba® (isavuconazole) sales
Basel/Allschwil, Switzerland, February 07, 2023 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting......